Home›Trial›NCT06146660
🔬NCT06146660RECRUITING

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Study Summary

The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.

Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions / Drugs
Mavacamten
View on ClinicalTrials.gov ↗
Sponsor
BMY
Bristol-Myers Squibb
Oncology
F35/100
Study Details
Enrollment600 participants
Primary Completion—
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.746655+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.